Financial Comparison: Akorn


Akorn and Warner Chilcott Plc are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations. Akorn currently has a consensus target price of $29.13, suggesting a potential downside of 12.48%.



from Biotech News